公开(公告)号：EP3200878A4

公开(公告)日：2018-05-30

申请号：EP15847978

申请日：2015-10-05

申请人： LOS ALAMOS NAT SECURITY LLC ,  UNIV OREGON HEALTH & SCIENCE ,  VIR BIOTECHNOLOGY INC

发明人： BRUENING ERIC ,  FRUEH KLAUS ,  PICKER LOUIS ,  KORBER BETTE T M ,  THEILER JAMES ,  MARSHALL EMILY

IPC分类号： A61P31/18 ,  A61K39/21

CPC分类号： A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/70 ,  C12N2710/16143 ,  C12N2740/16034 ,  C12N2740/16234

摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

公开(公告)号：EP2550362A4

公开(公告)日：2013-05-29

申请号：EP11760283

申请日：2011-03-25

申请人： UNIV OREGON HEALTH & SCIENCE

发明人： PICKER LOUIS ,  FRUEH KLAUS ,  HANSEN SCOTT G ,  POWERS COLIN

IPC分类号： C12N15/38 ,  A61K39/245 ,  C12N7/00 ,  C12N15/86

CPC分类号： G01N33/56972 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/02 ,  A61K39/12 ,  A61K39/21 ,  A61K39/245 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2710/10343 ,  C12N2710/16134 ,  C12N2710/16143 ,  C12N2710/24143 ,  C12N2740/10034 ,  C12N2740/15043

摘要： This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US 11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.

公开(公告)号：EP1307539A4

公开(公告)日：2004-04-28

申请号：EP01970530

申请日：2001-08-01

申请人： ORTHO MCNEIL PHARM INC ,  UNIV OREGON HEALTH & SCIENCE

发明人： LUUKKONEN MATTIAS ,  MOSES ASHLEE ,  FRUEH KLAUS ,  NELSON JAY ,  BELL YOLANDA ,  HEINRICH MICHAEL ,  SIMMEN KENNETH

IPC分类号： G01N33/53 ,  A61K31/00 ,  A61K31/07 ,  A61K31/337 ,  A61K31/704 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  A61P31/22 ,  C12M1/00 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  G01N21/77 ,  G01N21/78 ,  G01N33/58 ,  G01N37/00 ,  A61K47/48 ,  A61K31/203 ,  A61K31/445 ,  A61K31/55 ,  A61K38/16 ,  A61K38/19 ,  A61P35/00 ,  B01J19/00

CPC分类号： C12Q1/6883 ,  A61K31/00 ,  A61K31/337 ,  A61K31/704 ,  A61K38/212 ,  A61K45/06 ,  C12Q1/6837 ,  C12Q2600/158 ,  G06Q50/22 ,  Y02A90/22 ,  A61K2300/00

摘要： The present invention utilizes nucleic acid microarray technology to identify changes in the host endothelial cell transcription pattern that occurs during the latent and lytic phase of the KSHV life cycle. The production or activity of some genes up regulated during the lytic cycle were subsequently inhibited, and two such targets were shown to have a role in expression of late viral genes. Using this combined approach we have identified cellular pathways previously unknown to be important for KSHV infection, and present evidence for the efficiency of the novel antiviral approaches thus discovered. In addition, the present invention identifies a wide variety of endothelial cells genes and pathways that are involved in a variety of endothelial cell-mediated activity, including angiogenesis and transformation.

公开(公告)号：EP2964769A4

公开(公告)日：2016-08-31

申请号：EP14759837

申请日：2014-03-05

申请人： UNIV OREGON HEALTH & SCIENCE

发明人： PICKER LOUIS ,  HANSEN SCOTT ,  FRUEH KLAUS ,  MALOULI DANIEL

IPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/12

CPC分类号： C12N15/86 ,  A61K39/04 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16011 ,  C12N2710/16143 ,  C12N2740/15034

摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.

公开(公告)号：EP2569436A4

公开(公告)日：2013-11-27

申请号：EP11781407

申请日：2011-05-16

申请人： UNIV OREGON HEALTH & SCIENCE

发明人： PICKER LOUIS ,  NELSON JAY A ,  FRUEH KLAUS ,  JARVIS MICHAEL A ,  HANSEN SCOTT G

IPC分类号： C12N15/869 ,  A61K39/12 ,  A61P31/12 ,  A61P35/00 ,  C12N15/33

CPC分类号： C12N7/00 ,  A61K39/0011 ,  A61K39/08 ,  A61K39/12 ,  A61K39/13 ,  A61K39/145 ,  A61K39/275 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/58 ,  C07K14/005 ,  C07K14/045 ,  C07K14/16 ,  C07K14/161 ,  C07K14/162 ,  C07K14/163 ,  C12N15/86 ,  C12N15/869 ,  C12N2710/16111 ,  C12N2710/16134 ,  C12N2710/16141 ,  C12N2710/16143 ,  C12N2710/16162 ,  C12N2710/16171 ,  C12N2710/24134 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2760/14134 ,  C12N2760/16134 ,  C12N2770/32634

摘要： Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread.

摘要翻译： 本文描述了编码异源抗原如病原体特异性抗原或肿瘤抗原的重组恒河猴巨细胞病毒（RhCMV）和人巨细胞病毒（HCMV）载体。 重组载体引发和维持对异源抗原特异性的高水平细胞和体液免疫应答。 重组RhCMV和HCMV载体可用于例如治疗或预防感染性疾病或癌症。 在一些实例中，重组RhCMV或HCMV载体可以包括编码免疫调节蛋白的基因中的缺失。 在一些实例中，重组RhCMV或HCMV载体在细胞内复制的能力可能是缺陷或受损的，在宿主内传播或通过在CMV复制，传播或扩增中必需或增加的一个或多个基因中包含缺失而在宿主中扩散 传播。